JP2018509470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509470A5 JP2018509470A5 JP2018501141A JP2018501141A JP2018509470A5 JP 2018509470 A5 JP2018509470 A5 JP 2018509470A5 JP 2018501141 A JP2018501141 A JP 2018501141A JP 2018501141 A JP2018501141 A JP 2018501141A JP 2018509470 A5 JP2018509470 A5 JP 2018509470A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- amount
- fexofenadine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229960003592 fexofenadine Drugs 0.000 claims 8
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 8
- 229960003940 naproxen sodium Drugs 0.000 claims 7
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 7
- 239000000739 antihistaminic agent Substances 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 229940124623 antihistamine drug Drugs 0.000 claims 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- -1 ketorofen Chemical compound 0.000 claims 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 229960001803 cetirizine Drugs 0.000 claims 3
- 229960001271 desloratadine Drugs 0.000 claims 3
- 229960001680 ibuprofen Drugs 0.000 claims 3
- 229960003088 loratadine Drugs 0.000 claims 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- 229960005293 etodolac Drugs 0.000 claims 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229960004752 ketorolac Drugs 0.000 claims 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
- 229960001929 meloxicam Drugs 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 229960000953 salsalate Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 229960001017 tolmetin Drugs 0.000 claims 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138665P | 2015-03-26 | 2015-03-26 | |
| US62/138,665 | 2015-03-26 | ||
| PCT/US2016/023200 WO2016154028A1 (en) | 2015-03-26 | 2016-03-18 | Methods and compositions to inhibit symptoms associated with veisalgia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509470A JP2018509470A (ja) | 2018-04-05 |
| JP2018509470A5 true JP2018509470A5 (enExample) | 2019-05-09 |
| JP6851365B2 JP6851365B2 (ja) | 2021-03-31 |
Family
ID=56976188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501141A Active JP6851365B2 (ja) | 2015-03-26 | 2016-03-18 | 宿酔に伴う症状を抑制するための方法及び組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10420756B2 (enExample) |
| EP (2) | EP3273952B1 (enExample) |
| JP (1) | JP6851365B2 (enExample) |
| KR (1) | KR102597910B1 (enExample) |
| CN (2) | CN115887456A (enExample) |
| AU (1) | AU2016235484B2 (enExample) |
| BR (1) | BR112017020307B1 (enExample) |
| CA (1) | CA2980162C (enExample) |
| ES (1) | ES2926494T3 (enExample) |
| IL (1) | IL254641B2 (enExample) |
| MX (2) | MX390011B (enExample) |
| NZ (1) | NZ735777A (enExample) |
| PL (1) | PL3273952T3 (enExample) |
| WO (1) | WO2016154028A1 (enExample) |
| ZA (1) | ZA201706794B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102597910B1 (ko) * | 2015-03-26 | 2023-11-02 | 재클린 엠. 이베르센 | 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 |
| US20180360811A1 (en) * | 2017-06-16 | 2018-12-20 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections |
| WO2019046201A1 (en) * | 2017-08-30 | 2019-03-07 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION |
| US11129803B2 (en) | 2017-09-18 | 2021-09-28 | SEN-JAM Pharmaceutical LLC | Methods and compositions to inhibit tolerance to opioids |
| WO2019055939A1 (en) * | 2017-09-18 | 2019-03-21 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING |
| US10675261B2 (en) | 2017-09-18 | 2020-06-09 | SEN-JAM Pharmaceutical LLC | Methods and compositions to inhibit dependence on opioids |
| WO2019178516A1 (en) * | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075426A (en) | 1976-03-12 | 1978-02-21 | Harvey Mitchell Gould | Parallel silent communicator |
| US4496548A (en) * | 1983-02-04 | 1985-01-29 | Moldowan Mervin J | Composition and method for reducing hangover |
| US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
| US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| WO1992005783A1 (en) * | 1990-09-28 | 1992-04-16 | Merck & Co., Inc. | Ibuprofen-antihistamine combinations |
| FI950467A7 (fi) * | 1992-08-03 | 1995-03-31 | Sepracor Inc | Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi |
| EP0766960B1 (en) | 1995-04-21 | 2003-09-17 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| DE19708209C2 (de) | 1997-02-28 | 2000-03-02 | Hans Juergen Pauling | Wiederaufladbare Batterieanordnung und deren Verwendung |
| US20050281751A1 (en) | 1997-07-21 | 2005-12-22 | Bruce Levin | Directed intranasal administration of pharmaceutical agents |
| BR9812660A (pt) * | 1997-09-19 | 2000-08-22 | Procter & Gamble | Composições e métodos para tratar distúrbios respiratórios |
| US20030181495A1 (en) | 1998-06-23 | 2003-09-25 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6596770B2 (en) | 2000-05-05 | 2003-07-22 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6697361B2 (en) | 1998-09-15 | 2004-02-24 | Nortel Networks Limited | Method and apparatus for stream aggregation in a multiprotocol label switching network environment |
| US6274627B1 (en) | 1999-10-12 | 2001-08-14 | Medinox, Inc. | Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor |
| WO2003009834A1 (en) | 2000-08-17 | 2003-02-06 | Battey Alyce S | Oral delivery of pharmaceuticals via encapsulation |
| US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| US7189757B2 (en) | 2001-10-16 | 2007-03-13 | Hypnion, Inc. | Treatment of sleep disorders using CNS target modulators |
| WO2003032912A2 (en) | 2001-10-16 | 2003-04-24 | Hypnion, Inc. | Treatment of cns disorders using cns target modulators |
| GB0128674D0 (en) | 2001-11-30 | 2002-01-23 | Boots Co Plc | Treatment of sleep disorders and the like |
| EP1471913A2 (en) | 2002-01-18 | 2004-11-03 | Hypnion Inc. | Treatment of sleep disorders using sleep target modulators |
| DE10223147A1 (de) | 2002-05-16 | 2003-11-27 | Newfrey Llc | Fügesystemkopf, Fügesystem und Verfahren zum Zuführen und Fügen von Elementen |
| AU2003231063A1 (en) * | 2002-08-15 | 2004-03-03 | Louis P. Scafuri | Composition and method for controlling alcohol-induced facial flushing in susceptible humans |
| US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| CL2003002653A1 (es) * | 2002-12-18 | 2005-04-22 | Wyeth Corp | Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar |
| US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| GB0312425D0 (en) | 2003-05-30 | 2003-07-09 | Boots Co Plc | Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith |
| GB0312419D0 (en) | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
| US20070292498A1 (en) | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| TW200534852A (en) * | 2004-03-03 | 2005-11-01 | Convivia | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| US20110053999A1 (en) | 2004-03-03 | 2011-03-03 | Daley Thomas E | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| GB2435410B (en) * | 2004-04-21 | 2007-12-05 | Silent Gliss Internat Ltd | Improvements in or relating to curtain heading systems |
| EP1782831B1 (en) | 2004-08-18 | 2011-10-19 | Medrx Co., Ltd. | External preparation |
| DK1804804T3 (da) | 2004-09-21 | 2012-02-20 | Hypnion Inc | 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| WO2006049734A2 (en) | 2004-10-29 | 2006-05-11 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| CA2588943C (en) | 2004-12-15 | 2013-02-26 | Saitama Daiichi Pharmaceutical Co., Ltd. | Medical tape preparation |
| AU2005316295B2 (en) | 2004-12-17 | 2012-03-22 | Alan B. Cash | Method for extending lifespan and delaying the onset of age-related disease |
| JPWO2006087968A1 (ja) | 2005-02-17 | 2008-07-03 | 角治 東條 | 眼科用固形外用薬剤 |
| US20070093520A1 (en) | 2005-04-15 | 2007-04-26 | Caras Steven D | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject |
| US20070086974A1 (en) * | 2005-10-06 | 2007-04-19 | Gawande Rahul S | Cetirizine compositions |
| US20070196518A1 (en) | 2005-12-15 | 2007-08-23 | Karol Wojewnik | Composition and Method for Mitigating a Negative Effect of Alcohol Consumption |
| WO2007092334A1 (en) | 2006-02-02 | 2007-08-16 | Hypnion, Inc. | Method of treating sleep disorders |
| WO2007092333A1 (en) | 2006-02-03 | 2007-08-16 | Hypnion, Inc. | Use of olopatadine for treating sleep disorders |
| GB2435418A (en) * | 2006-02-28 | 2007-08-29 | Amalan Selvarajah | Composition for preventing and alleviating alcohol hangover |
| WO2007103474A2 (en) | 2006-03-07 | 2007-09-13 | University Of Florida Research Foundation, Inc. | Drug adherence monitoring system |
| US20080131532A1 (en) | 2006-10-17 | 2008-06-05 | Lorn Leitman | Fast asleep |
| US20080113021A1 (en) * | 2006-10-25 | 2008-05-15 | Robert Shen | Ibuprofen composition |
| JP2010513569A (ja) | 2006-12-19 | 2010-04-30 | ユニバーシティ オブ バージニア パテント ファウンデーション | アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果 |
| US20100076006A1 (en) | 2007-01-31 | 2010-03-25 | University Of Virginia Patent Foundation | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| WO2009051628A2 (en) | 2007-09-06 | 2009-04-23 | Arezou Petrie | Transdermal treatment device and method |
| EP2214478A1 (en) | 2007-10-19 | 2010-08-11 | Innozen, Inc. | Composition for administering an active ingredient and method for making and using the same |
| WO2009089134A1 (en) * | 2008-01-04 | 2009-07-16 | Src, Inc. | Methods for measuring a patint response upon administration of a drug and compositions thereof |
| US8440632B2 (en) * | 2008-01-24 | 2013-05-14 | Raptor Therapeutics Inc. | Protopanaxadiol-type ginsenoside compositions and uses thereof |
| US20090258869A1 (en) | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| ES2430940T3 (es) | 2008-02-28 | 2013-11-22 | University Of Virginia Patent Foundation | Gen del transportador de serotonina y tratamiento del alcoholismo |
| EP2288355A1 (en) * | 2008-05-30 | 2011-03-02 | Fairfield Clinical Trials LLC | Method and composition for skin inflammation and discoloration |
| CA2765866C (en) | 2008-06-20 | 2016-06-21 | Alphapharm Pty Ltd | Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid |
| US20130029970A1 (en) | 2009-07-10 | 2013-01-31 | Ironwood Pharmaceuticals, Inc | CB Receptor Agonists |
| EP2995303A1 (en) | 2009-07-10 | 2016-03-16 | President and Fellows of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| US20130109721A1 (en) | 2009-12-08 | 2013-05-02 | Ironwood Pharmaceuticals, Inc. | FAAH Inhibitors |
| WO2011075688A1 (en) | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions |
| US20130178453A1 (en) | 2010-02-09 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Agonists |
| US20130196960A1 (en) | 2010-02-09 | 2013-08-01 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Receptor Agonists |
| WO2012048294A2 (en) | 2010-10-07 | 2012-04-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| WO2012088431A1 (en) | 2010-12-23 | 2012-06-28 | Ironwood Pharmaceuticals, Inc. | Faah inhibitors |
| JP2014506894A (ja) | 2011-02-28 | 2014-03-20 | テクノロジーズ・クロロス・インク | 口腔吸収用の咀嚼可能なビヒクル |
| RS66303B1 (sr) | 2011-05-20 | 2025-01-31 | H Lundbeck As | Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene |
| US9161957B2 (en) * | 2012-08-03 | 2015-10-20 | Life Well Lived, Llc | Compositions and methods for reducing blood alcohol content |
| JP6276944B2 (ja) * | 2013-08-29 | 2018-02-07 | 興和株式会社 | フェキソフェナジンとｎｓａｉｄ含有医薬組成物 |
| WO2015073573A1 (en) * | 2013-11-14 | 2015-05-21 | Jacobs Michael M | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
| KR102597910B1 (ko) | 2015-03-26 | 2023-11-02 | 재클린 엠. 이베르센 | 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 |
| WO2019178516A1 (en) * | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
-
2016
- 2016-03-18 KR KR1020177031097A patent/KR102597910B1/ko active Active
- 2016-03-18 BR BR112017020307-3A patent/BR112017020307B1/pt active IP Right Grant
- 2016-03-18 EP EP16769429.8A patent/EP3273952B1/en active Active
- 2016-03-18 ES ES16769429T patent/ES2926494T3/es active Active
- 2016-03-18 CN CN202211634942.6A patent/CN115887456A/zh active Pending
- 2016-03-18 NZ NZ735777A patent/NZ735777A/en unknown
- 2016-03-18 CA CA2980162A patent/CA2980162C/en active Active
- 2016-03-18 US US15/074,524 patent/US10420756B2/en active Active
- 2016-03-18 JP JP2018501141A patent/JP6851365B2/ja active Active
- 2016-03-18 EP EP21208021.2A patent/EP3973957A1/en active Pending
- 2016-03-18 PL PL16769429.8T patent/PL3273952T3/pl unknown
- 2016-03-18 AU AU2016235484A patent/AU2016235484B2/en active Active
- 2016-03-18 CN CN201680030862.6A patent/CN107635549A/zh active Pending
- 2016-03-18 MX MX2017012132A patent/MX390011B/es unknown
- 2016-03-18 WO PCT/US2016/023200 patent/WO2016154028A1/en not_active Ceased
- 2016-03-18 IL IL254641A patent/IL254641B2/en unknown
-
2017
- 2017-09-25 MX MX2022001796A patent/MX2022001796A/es unknown
- 2017-10-09 ZA ZA2017/06794A patent/ZA201706794B/en unknown
-
2019
- 2019-09-17 US US16/573,384 patent/US11464766B2/en active Active
-
2022
- 2022-09-02 US US17/902,124 patent/US20230064685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601529A (en) | Tapentadol compositions | |
| AR076540A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor | |
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| McCarberg et al. | Evolving therapeutic strategies to improve nonsteroidal anti-inflammatory drug safety | |
| MA29115B1 (fr) | Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee | |
| JP2013509444A5 (enExample) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| IL194885A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid | |
| Moore | In search of an ideal analgesic for common acute pain | |
| UY33061A (es) | Composiciones para comprimidos desintegrables oralmente de ondansetrón para prevenir náuseas y vómitos | |
| IL254641B2 (en) | Methods and compositions comprising naproxen and fexofenadine to inhibit symptoms of dizziness associated with intake of alcohol | |
| AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
| WO2019055942A4 (en) | Methods and compositions to inhibit tolerance to opioids | |
| BR112013012100A2 (pt) | composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica | |
| DK2853262T3 (en) | Treatment of sunburn using analgesics and antihistamines | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. | |
| Manohar et al. | Prescribing pattern of gastroprotective agents with non-steroidal anti-inflammatory drugs | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| BRPI0809310A2 (pt) | Composição farmacêutica em forma de um comprimido sublingual que compreende um anti-inflamatório não esteroidal e um análgésico opiáceo para o controle da dor. | |
| US20150290174A1 (en) | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| ECSP088801A (es) | Composicion farmaceutica que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia | |
| ECSP11010999A (es) | Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina | |
| RU2012102980A (ru) | Лекарственное средство для длительного применения nsaid |